John E. Shively

27.2k total citations · 1 hit paper
420 papers, 20.1k citations indexed

About

John E. Shively is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, John E. Shively has authored 420 papers receiving a total of 20.1k indexed citations (citations by other indexed papers that have themselves been cited), including 217 papers in Molecular Biology, 175 papers in Radiology, Nuclear Medicine and Imaging and 142 papers in Oncology. Recurrent topics in John E. Shively's work include Monoclonal and Polyclonal Antibodies Research (121 papers), Radiopharmaceutical Chemistry and Applications (119 papers) and Peptidase Inhibition and Analysis (62 papers). John E. Shively is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (121 papers), Radiopharmaceutical Chemistry and Applications (119 papers) and Peptidase Inhibition and Analysis (62 papers). John E. Shively collaborates with scholars based in United States, Germany and Japan. John E. Shively's co-authors include H. Edward Conrad, Andrew Raubitschek, David H. Hawke, Mitsuru Haniu, Peter F. Hall, Joseph R. Reeve, Lawrence E. Williams, Anna M. Wu, Paul J. Yazaki and J. David Beatty and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

John E. Shively

416 papers receiving 19.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Formation of anhydrosugars in the chemical depolymerization of heparin

1976 856 citations John E. Shively et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John E. Shively United States	74	9.8k	5.6k	4.3k	2.3k	2.2k	420	20.1k
Mark C. Willingham United States	90	17.6k 1.8×	2.7k 0.5×	9.4k 2.2×	1.1k 0.5×	5.5k 2.5×	425	33.5k
Harvey R. Herschman United States	81	12.5k 1.3×	1.8k 0.3×	3.7k 0.9×	1.9k 0.8×	2.9k 1.3×	330	25.2k
William J. Henzel United States	63	16.3k 1.7×	1.3k 0.2×	4.2k 1.0×	2.9k 1.3×	6.4k 2.9×	117	28.6k
Lawrence Levine United States	63	7.8k 0.8×	1.3k 0.2×	2.0k 0.5×	1.5k 0.6×	1.6k 0.7×	316	17.6k
Pedro Cuatrecasas United States	104	23.0k 2.3×	2.6k 0.5×	2.4k 0.5×	6.6k 2.8×	3.4k 1.5×	362	35.6k
Robert J. Coffey United States	98	16.7k 1.7×	1.5k 0.3×	7.8k 1.8×	1.2k 0.5×	2.8k 1.3×	416	34.1k
Larry A. Sklar United States	71	10.5k 1.1×	975 0.2×	2.1k 0.5×	1.5k 0.6×	2.8k 1.3×	319	19.1k
Brian Seed United States	77	17.8k 1.8×	3.6k 0.6×	5.0k 1.2×	1.1k 0.5×	11.8k 5.4×	155	33.2k
John T. Isaacs United States	79	10.9k 1.1×	1.0k 0.2×	5.4k 1.3×	729 0.3×	1.8k 0.8×	311	21.3k
Enrique Rozengurt United Kingdom	99	22.2k 2.3×	915 0.2×	5.1k 1.2×	5.2k 2.2×	2.4k 1.1×	504	32.9k

Countries citing papers authored by John E. Shively

Since Specialization

Citations

This map shows the geographic impact of John E. Shively's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John E. Shively with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John E. Shively more than expected).

Fields of papers citing papers by John E. Shively

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John E. Shively. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John E. Shively. The network helps show where John E. Shively may publish in the future.

Co-authorship network of co-authors of John E. Shively

This figure shows the co-authorship network connecting the top 25 collaborators of John E. Shively. A scholar is included among the top collaborators of John E. Shively based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John E. Shively. John E. Shively is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Adhikarla, Vikram, Enrico Caserta, Xiuli Wang, et al.. (2024). Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers. Cancer Research Communications. 4(11). 2955–2967. 1 indexed citations

Kujawski, Maciej, Dennis Awuah, Edward Seung, et al.. (2024). Targeting CEA in metastatic triple negative breast cancer with image-guided radiation followed by Fab-mediated chimeric antigen receptor (CAR) T-cell therapy. Frontiers in Immunology. 15. 1499471–1499471. 1 indexed citations

Hernandez, Matthew C., Paul J. Yazaki, Joanne Mortimer, et al.. (2023). Pilot study of HER2 targeted 64Cu-DOTA-tagged PET imaging in gastric cancer patients. Nuclear Medicine Communications. 44(12). 1151–1155. 4 indexed citations

Zhang, Zhifang, et al.. (2022). Reversal of obesity development in Ceacam1^−/− male mice by bone marrow transplantation or introduction of the human CEACAM1 gene. Obesity. 30(7). 1351–1356. 5 indexed citations

Hu, Weidong, Karine Bagramyan, Teresa Hong, et al.. (2021). Phosphorylation of human CEACAM1-LF by PKA and GSK3β promotes its interaction with β-catenin. Journal of Biological Chemistry. 297(5). 101305–101305. 6 indexed citations

Kujawski, Maciej, Mark E. Sherman, Susanta Hui, et al.. (2020). Potent immunomodulatory effects of an anti-CEA-IL-2 immunocytokine on tumor therapy and effects of stereotactic radiation. OncoImmunology. 9(1). 1724052–1724052. 17 indexed citations

Li, Lin, Paul J. Yazaki, Junie Chea, et al.. (2020). Improved targeting of an anti‐TAG‐72 antibody drug conjugate for the treatment of ovarian cancer. Cancer Medicine. 9(13). 4756–4767. 15 indexed citations

Kujawski, Maciej, Lin Li, S. Bhattacharya, et al.. (2019). Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy. BMC Cancer. 19(1). 882–882. 17 indexed citations

Leong, Lucille, Lawrence D. Wagman, Stephen Shibata, et al.. (2017). Phase I/II Trial of Anticarcinoembryonic Antigen Radioimmunotherapy, Gemcitabine, and Hepatic Arterial Infusion of Fluorodeoxyuridine Postresection of Liver Metastasis for Colorectal Carcinoma. Cancer Biotherapy and Radiopharmaceuticals. 32(7). 258–265. 11 indexed citations

10.

Wong, Patty, Lin Li, Junie Chea, et al.. (2017). Synthesis, Positron Emission Tomography Imaging, and Therapy of Diabody Targeted Drug Lipid Nanoparticles in a Prostate Cancer Murine Model. Cancer Biotherapy and Radiopharmaceuticals. 32(7). 247–257. 13 indexed citations

11.

Lu, Rongze, Maciej Kujawski, Hao Pan, & John E. Shively. (2012). Tumor Angiogenesis Mediated by Myeloid Cells Is Negatively Regulated by CEACAM1. Cancer Research. 72(9). 2239–2250. 30 indexed citations

12.

Li, Chunxia, Mitsuo Kato, Lily Shiue, et al.. (2006). Cell Type and Culture Condition–Dependent Alternative Splicing in Human Breast Cancer Cells Revealed by Splicing-Sensitive Microarrays. Cancer Research. 66(4). 1990–1999. 69 indexed citations

13.

Wong, Jeffrey Y.C., David Z. J. Chu, Lawrence E. Williams, et al.. (2006). A Phase I Trial of ⁹⁰ Y-DOTA-Anti-CEA Chimeric T84.66 (cT84.66) Radioimmunotherapy in Patients with Metastatic CEA-Producing Malignancies. Cancer Biotherapy and Radiopharmaceuticals. 21(2). 88–100. 38 indexed citations

14.

Olafsen, Tove, Vania Kenanova, Gobalakrishnan Sundaresan, et al.. (2005). Optimizing Radiolabeled Engineered Anti-p185HER2 Antibody Fragments for In vivo Imaging. Cancer Research. 65(13). 5907–5916. 123 indexed citations

15.

Crow, Desiree, Lawrence E. Williams, David Colcher, et al.. (2005). Combined Radioimmunotherapy and Chemotherapy of Breast Tumors with Y-90-Labeled Anti-Her2 and Anti-CEA Antibodies with Taxol. Bioconjugate Chemistry. 16(5). 1117–1125. 26 indexed citations

16.

Williams, Lawrence E., Anna M. Wu, Paul J. Yazaki, et al.. (2001). Numerical Selection of Optimal Tumor Imaging Agents with Application to Engineered Antibodies. Cancer Biotherapy and Radiopharmaceuticals. 16(1). 25–35. 48 indexed citations

17.

Shively, John E., et al.. (1991). Structural analysis of proteins by laser desorption and electrospray mass spectrometry. Current Opinion in Biotechnology. 2(1). 52–60. 1 indexed citations

18.

Schrewe, Heinrich, John A. Thompson, Marion Bona, et al.. (1990). Cloning of the Complete Gene for Carcinoembryonic Antigen. Molecular and Cellular Biology. 2 indexed citations

19.

Chen, Shiuan, Marc J. Besman, Robert S. Sparkes, et al.. (1988). Human Aromatase: cDNA Cloning, Southern Blot Analysis, and Assignment of the Gene to Chromosome 15. DNA. 7(1). 27–38. 188 indexed citations

20.

Wetzel, Ronald, L. Jeanne Perry, David A. Estell, et al.. (1981). Properties of a Human Alpha-Interferon Purified from E. Coli Extracts. Journal of Interferon Research. 1(3). 381–390. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact